Evolent Health, Inc.

EVH • Medical - Healthcare Information Services

$4.32

▲ +0.06 (+1.41%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$486.18M

Growth

39.4%

Cash Flow

3/5

Trend

Mostly stable

Evidence

Positive revenue growth · 11.7%Positive free cash flow · 0.04Healthy liquidity · 1.31High debt level · 2.38Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:24 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$4.32

Change1.41%

Shares Out112.54M

Market Cap$486.18M

Enterprise Value$374.45M

52W Range2.10 - 10.08

Beta0.77

P/E-0.96

P/S0.23

P/B1.27

P/FCF12.00

EV/Sales0.18

Price$4.32

Change1.41%

Shares Out112.54M

Market Cap$486.18M

Enterprise Value$374.45M

52W Range2.10 - 10.08

Beta0.77

P/E-0.96

P/S0.23

P/B1.27

P/FCF12.00

EV/Sales0.18

EV/EBITDA6.90

EV/FCF9.25

Earnings Yield-103.87%

FCF Yield8.33%

Dividend Yield0.39%

Gross Margin15.14%

Oper. Margin-0.24%

Profit Margin-28.49%

Debt/Eq2.38

Current Ratio1.31

Quick Ratio1.31

Revenue 5Y39.43%

Target$7.00

Target Upside62.04%

Target Median$7.00

Target Range7.00 - 7.00

Volume7.06M

Avg Volume2.73M

EPS Surprise0.03

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

49/100

Growth Potential

Revenue and expansion

58/100

Price Attractiveness

Cheap or expensive today

72/100

Why this score▼

Positive revenue growth · 11.7%Positive free cash flow · 0.04Healthy liquidity · 1.31High debt level · 2.38Weak profitability

Analyst view

Analyst sentiment and price target

EVH

Analyst sentiment

Based on 30 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$3.50

Mean

$5.83

Median

$7.00

High

$7.00

Company Overview

IPO: 6/5/2015

Industry: Medical - Healthcare Information Services

P/B i: 1.27

Debt / Equity i: 2.38

Operating Margin: -0.24%

Net Margin: -28.49%

ROE i: -

ROIC: -

Financial Health

Score10 / 20

Debt / Equity: 2.38

Current Ratio: 1.31

Quick Ratio: 1.31

Status: Moderate

Warnings

High debt level

Insider Transactions

Recent executive and insider activity

Shams Aammaad

Transaction: 07/01/2026

BUY

Change

+28,790

Price

Not reported

Filing

07/06/2026

Type

BUY

McCarthy Daniel Joseph

Transaction: 07/01/2026

SELL

Change

-4,582

Price

$5.74

Filing

07/06/2026

Type

SELL

Weinberg Jonathan

Transaction: 07/01/2026

SELL

Change

-2,650

Price

$5.74

Filing

07/06/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Shams Aammaad	BUY	+28,790	Not reported	07/01/2026	07/06/2026
McCarthy Daniel Joseph	SELL	-4,582	$5.74	07/01/2026	07/06/2026
Weinberg Jonathan	SELL	-2,650	$5.74	07/01/2026	07/06/2026
Blackley Seth	SELL	-10,297	$5.74	07/01/2026	07/06/2026
Barbarosh Craig A.	BUY	+41,096	Not reported	06/04/2026	06/08/2026
Springstubb Brendan B	BUY	+41,096	Not reported	06/04/2026	06/08/2026
Smith Jill D.	BUY	+41,096	Not reported	06/04/2026	06/08/2026
KECK KIM	BUY	+41,096	Not reported	06/04/2026	06/08/2026
Jelinek Richard M	BUY	+41,096	Not reported	06/04/2026	06/08/2026
GUERTIN SHAWN M	BUY	+41,096	Not reported	06/04/2026	06/08/2026
GRUA PETER J	BUY	+41,096	Not reported	06/04/2026	06/08/2026
Glass Russell Monroe	BUY	+41,096	Not reported	06/04/2026	06/08/2026
Ajayi Toyin	BUY	+41,096	Not reported	06/04/2026	06/08/2026
Shams Aammaad	SELL	-4,311	$3.51	03/03/2026	03/04/2026
McCarthy Daniel Joseph	SELL	-24,027	$3.51	03/03/2026	03/04/2026
Weinberg Jonathan	SELL	-8,275	$3.51	03/03/2026	03/04/2026
Blackley Seth	SELL	-24,053	$3.51	03/03/2026	03/04/2026
Ramos Mario	BUY	+429,041	Not reported	03/02/2026	03/04/2026
Shams Aammaad	BUY	+55,173	Not reported	03/02/2026	03/04/2026
Shams Aammaad	SELL	-850	$3.58	03/02/2026	03/04/2026

About the Company

Evolent Health, Inc.

Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.

Source - link

Peers

AMN AVBP BFLY HSTM KURA MGTX MYGN NUTX PSNL REPL

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.

Seeking Alpha

Dimensional Fund Advisors LP Has $4.08 Million Stock Position in Evolent Health, Inc $EVH

Dimensional Fund Advisors LP reduced its stake in Evolent Health, Inc (NYSE: EVH) by 22.4% during the quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,790,298 shares of the technology company's stock after selling 517,486 shares during the period. Dimensional Fund Advisors LP

Defense World

Evolent Health Q2 Earnings Call Highlights

Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.

MarketBeat

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Seeking Alpha

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	-0.05	-0.02	0.03
2026-02-24	0.06	0.08	0.02
2025-11-06	0.1	0.05	-0.05
2025-08-07	0.09	-0.1	-0.19
2025-05-08	0.09	0.06	-0.03
2025-02-20	0.38	-0.02	-0.4
2024-11-07	0.3	0.04	-0.26
2024-08-08	0.21	0.3	0.09
2024-05-09	0.21	0.34	0.13
2024-02-22	0.11	0.23	0.12
2023-11-02	0.09	0.3	0.21
2023-08-02	0.09	0.14	0.05